Spesolimab for preventing generalised pustular psoriasis flares

Spesolimab is currently in clinical development for flare prevention in patients with generalised pustular psoriasis (GPP). Individuals with GPP experience repeated episodes where large surface areas of the skin become inflamed and red, and develop small pus-filled blisters known as pustules. It is a disease that spreads and affects a large surface area of the body. The main cause of GPP is not yet known but it is thought that environmental factors such as stress and genetic susceptibility can trigger disease onset. GPP can be a life-threatening disease if left untreated. Deaths have been attributed to septic shock and cardiorespiratory failure.